Boston Scientific (BSX) Receivables (2009 - 2026)

Boston Scientific has disclosed Receivables across 18 years of filings, most recently posting $3.2 billion for Q1 2026.

• Receivables for Q1 2026 came in at $3.2 billion, up 12.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 billion (up 12.4% YoY), and the FY2025 annual result was $3.1 billion, up 14.66% from the prior year.
• Receivables came in at $3.2 billion for Q1 2026 at Boston Scientific, up from $3.1 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $3.2 billion in Q1 2026 to a low of $1.9 billion in Q1 2022.
• The 5-year median for Receivables is $2.4 billion (2024), against an average of $2.4 billion.
• Across the five-year window, Receivables climbed 4.45% in 2022 and grew 24.23% in 2024, its largest moves.
• Boston Scientific's Receivables stood at $2.0 billion in 2022, then grew by 18.68% to $2.3 billion in 2023, then advanced by 14.07% to $2.7 billion in 2024, then climbed by 14.66% to $3.1 billion in 2025, then rose by 3.14% to $3.2 billion in 2026.
• The last three Receivables figures came in at $3.2 billion (Q1 2026), $3.1 billion (Q4 2025), and $3.0 billion (Q3 2025), per Business Quant data.